skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
MAGE-3.A1 Peptide Vaccine (Code C48632)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: MAGE-3.A1 Peptide Vaccine

Definition: A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3) with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-3.A1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-3, resulting in tumor cell lysis. MAGE-3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.

Label: MAGE-3.A1 Peptide Vaccine

NCI Thesaurus Code: C48632 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL423799  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HLA-A1-Restricted MAGE-3 Peptide Vaccine
MAGE-3.A1 Peptide Vaccine

External Source Codes: 
NSC Code 731578 (see NCI DTP info)
PDQ Closed Trial Search ID 685200
PDQ Open Trial Search ID 685200 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C48632
Legacy_Concept_Name HLA-A1-Restricted_MAGE-3_Peptide
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom